Experience with liver and kidney allografts from non-heart-beating donors.

PubWeight™: 1.83‹?› | Rank: Top 3%

🔗 View Article (PMC 3035834)

Published in Transplantation on January 27, 1995


A Casavilla1, C Ramirez, R Shapiro, D Nghiem, K Miracle, O Bronsther, P Randhawa, B Broznick, J J Fung, T Starzl

Author Affiliations

1: Department of Surgery, Pittsburgh Transplantation Institute, University of Pittsburgh Medical Center, Pennsylvania.

Articles citing this

Part 8: Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation (2015) 2.16

Survival following liver transplantation from non-heart-beating donors. Ann Surg (2004) 1.96

Non-heart-beating organ donation in Canada: Time to proceed? CMAJ (2003) 1.90

Non-heart-beating organ donors as a source of kidneys for transplantation: a chart review. CMAJ (1999) 1.86

Lung transplantation: opportunities for research and clinical advancement. Am J Respir Crit Care Med (2005) 1.85

Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg (2005) 1.67

Liver transplantation after organ preservation with normothermic extracorporeal perfusion. Ann Surg (2001) 1.40

The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery (2009) 1.39

Novel short-term hypothermic oxygenated perfusion (HOPE) system prevents injury in rat liver graft from non-heart beating donor. Ann Surg (2006) 1.12

Current state of hypothermic machine perfusion preservation of organs: The clinical perspective. Cryobiology (2009) 1.11

Attenuation of ischemic liver injury by augmentation of endogenous adenosine. Transplantation (1997) 0.95

Single-center experience with liver transplantation from controlled non-heartbeating donors: a viable source of grafts. Ann Surg (2005) 0.93

Islam and end-of-life practices in organ donation for transplantation: new questions and serious sociocultural consequences. HEC Forum (2009) 0.91

Can the rat donor liver tolerate prolonged warm ischemia? World J Gastroenterol (2000) 0.85

Inhibition of inducible nitric oxide synthase prevents graft injury after transplantation of livers from rats after cardiac death. Liver Transpl (2010) 0.85

Liver transplantation from non-heart beating donors. BMJ (2006) 0.84

Non heart-beating donors in England. Clinics (Sao Paulo) (2008) 0.84

Utilization of expanded criteria donors in liver transplantation. Int J Organ Transplant Med (2013) 0.83

Allografts in soft tissue reconstructive procedures: important considerations. Sports Health (2014) 0.81

Changing pattern of donor selection criteria in deceased donor liver transplant: a review of literature. J Clin Exp Hepatol (2013) 0.80

Liver transplantation from a non-heart-beating donor after pulmonary failure: report of a case. Surg Today (2009) 0.79

Donation after cardio-circulatory death liver transplantation. World J Gastroenterol (2012) 0.78

Ischemic preconditioning of rat livers from non-heart-beating donors decreases parenchymal cell killing and increases graft survival after transplantation. HPB Surg (2012) 0.77

Kidney and liver transplants from donors after cardiac death: initial experience at the London Health Sciences Centre. Can J Surg (2010) 0.76

Liver transplantation: Current status and challenges. World J Gastroenterol (2016) 0.76

Challenges and advances in optimizing liver allografts from donation after circulatory death donors. J Nat Sci Biol Med (2016) 0.75

High-risk donors: expanding donor criteria. Transplant Proc (1999) 0.75

Anesthesia for liver transplantation from a maastricht category 4 non-heart-beating donor -A case report-. Korean J Anesthesiol (2010) 0.75

Modification of a biventricular assist device to facilitate preservative infusion and organ recovery in a nonheart-beating donor. J Extra Corpor Technol (2006) 0.75

Articles cited by this

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. JAMA (1968) 7.26

Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest (1955) 6.64

An improved technique for multiple organ harvesting. Surg Gynecol Obstet (1987) 4.73

Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc (1956) 3.94

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

Sinusoidal lining cell damage: the critical injury in cold preservation of liver allografts in the rat. Transplantation (1988) 1.78

Response to organ shortage: kidney retrieval programme using non-heart beating donors. BMJ (1994) 1.74

Renal grafts from non-heart beating donors. BMJ (1994) 1.47

Ischemic injury in liver transplantation: difference in injury sites between warm and cold ischemia in rats. Hepatology (1992) 1.42

Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology (1990) 1.38

Reflections on the first heart transplant. S Afr Med J (1987) 0.87

The puzzle people: memoirs of a transplant surgeon. Arch Surg (1992) 0.87

Ten-year experience in the use of double balloon catheter for kidney procurement from non-heart beating donors in cadaveric kidney transplantation. Clin Transplant (1993) 0.85

Acute vascular rejection with hemolytic uremic syndrome in kidneys from non-heart-beating donors: associated with secondary grafts and early cyclosporine treatment? Transplant Proc (1993) 0.85

Articles by these authors

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09

Kidney transplantation under FK 506. JAMA (1990) 7.45

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

An improved technique for multiple organ harvesting. Surg Gynecol Obstet (1987) 4.73


Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem (1973) 4.44

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet (2001) 3.86

The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85

Properties of proteins MPB64, MPB70, and MPB80 of Mycobacterium bovis BCG. Infect Immun (1986) 3.80

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49


Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Deamination of cytosine derivatives by bisulfite. Mechanism of the reaction. J Am Chem Soc (1974) 2.92

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75


Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Medical education and health for all. Aust J Public Health (1995) 2.65

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48

Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol (2000) 2.38

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30

Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J (1999) 2.28

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

On the reaction of guanine with glyoxal, pyruvaldehyde, and kethoxal, and the structure of the acylguanines. A new synthesis of N2-alkylguanines. Biochemistry (1969) 2.25

MPB59, a widely cross-reacting protein of Mycobacterium bovis BCG. Int Arch Allergy Appl Immunol (1986) 2.25

Overview: deinstitutionalization of psychiatric patients, a critical review of outcome studies. Am J Psychiatry (1981) 2.24

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22

Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16

A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant (2010) 2.14

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

Characteristic ribonucleolytic activity of human angiogenin. Biochemistry (1986) 2.06

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant (2014) 2.00

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99

Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95

Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93

Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88

Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88

The point system for organ distribution. Transplant Proc (1989) 1.88

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86

The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83

BK polyomavirus in solid organ transplantation. Am J Transplant (2013) 1.83

Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82

Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81

Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80

Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78

Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc (1991) 1.77

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution. EMBO J (1997) 1.77

Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75